Post Holdings delivered a solid Q4 2024 performance anchored by the Pet acquisition-driven growth and a favorable mix shift alongside ongoing cost optimization. Consolidated net sales were $2.01 billion, with adjusted EBITDA of $349 million, reflecting a 3% YoY top-line lift and an EBITDA uplift primarily driven by Pet and Weetabix contributions, completed ERP enhancements, and manufacturing efficiency gains. Management highlighted that over the past two years, adjusted EBITDA grew 45%, supported by organic growth and pet acquisitions, and that free cash flow exceeded $1 billion across the period. The company emphasized that 2025 should see a more normalized operating environment, with inflation stabilizing but consumer volumes still under pressure, and a continued emphasis on cost-out opportunities and capital allocation flexibility (including opportunistic M&A) while prioritizing balance sheet resilience.